Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 363-364, 2007; 10.1373/clinchem.2006.080903
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, F.
Right arrow Articles by Boudou, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, F.
Right arrow Articles by Boudou, P.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2007;53:363-364.)
© 2007 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Divergence in Classification of 25-Hydroxyvitamin D Status with Respect to Immunoassays

Fidaa Ibrahim, Christine Parmentier and Philippe Boudoua

Unit of Hormonal Biology, Hôpital Saint-Louis, Assistance Publique, Hôpitaux de Paris, Paris, France

aAddress correspondence to this author at: Unit of Hormonal Biology, Saint-Louis University Hospital (AP-HP) and INSERM U 671, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, France. Fax 33-1-42-49-42-80; e-mail philippe.boudou@sls.aphp.fr.

The first 20% of the full text of this article appears below.


To the Editor:

The major problem in measuring 25-hydroxyvitamin D (25-OHD) is attributable to the molecule itself (1). Thus, an analytical method must be selected that will accurately estimate total circulating 25-OHD independent of the circulating concentrations of 25OHD2 and 25OHD3. Although HPLC remains the method of choice, many convergent data indicate that the 25-OHD RIA (DiaSorin Inc) should be incorporated as a secondary reference method (2)(3). With the RIA method actually used in our laboratory, we evaluated the 25-OHD LIAISON® chemiluminescent immunoassay (CLIA) proposed by the same manufacturer as an alternative assay. We also investigated whether a 25-OHD value <50 nmol/L, a well-known arbitrary RIA cutoff value to define vitamin D insufficiency, is applicable to CLIA.

We studied 199 people [79 men/120 women; mean (SD) age 48.1 (19.8) years] who were residents of Paris and its suburbs and who suffered primary hyperparathyroidism (HPT), secondary HPT with hemodialysis or obesity, mild asthenia, depression, and/or osteopenia/osteoporosis. This study was approved by the ethics . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. Hypponen, S. Turner, P. Cumberland, C. Power, and I. Gibb
Serum 25-Hydroxyvitamin D Measurement in a Large Population Survey with Statistical Harmonization of Assay Variation to an International Standard
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4615 - 4622.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.